LUSUTROMBOPAG

Search structure
Trade Names:
Synonyms:
Status: Approved (2018)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: B02BX07
UNII: 6LL5JFU42F

Structure
InChI Key NOZIJMHMKORZBA-KJCUYJGMSA-N
Smile CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
InChI
InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C29H32Cl2N2O5S
Molecular Weight 591.56
AlogP 8.52
Hydrogen Bond Acceptor 6.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 13.0
Polar Surface Area 97.75
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 39.0

Pharmacology

Action Mechanism of Action Reference
AGONIST Thrombopoietin receptor agonist FDA
Primary Target
Thrombopoietin receptor

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Purpura, Thrombocytopenic, Idiopathic 2 D016553 ClinicalTrials

Related Entries

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Hepatobiliary disorders
21.28
Gastrointestinal disorders
14.89
Vascular disorders
12.77
Blood and lymphatic system disorders
10.64
Eye disorders
8.51
Cardiac disorders
6.38
Metabolism and nutrition disorders
6.38
Nervous system disorders
6.38
Investigations
4.26
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
4.26
General disorders and administration site conditions
2.13
Injury, poisoning and procedural complications
2.13

Cross References

Resources Reference
CAS NUMBER 1110766-97-6
ChEBI 136051
ChEMBL CHEMBL2107831
DrugBank DB13125
DrugCentral 5059
FDA SRS 6LL5JFU42F
Guide to Pharmacology 10032
PubChem 49843517
SureChEMBL SCHEMBL3062080
ZINC ZINC000084759273
CONTENTS